Eli Lilly revenue rises on continued tirzepatide demand
The drugmaker's quarterly results were driven by its incretin franchise, which continues to expand in diabetes and obesity.
The wire
- 01Eli Lilly reported higher revenue, which the company attributes to sustained demand for its GLP-1 products.
- 02Lilly's incretin sales set the pace for supply, pricing and compounding conditions that clinicians and telehealth operators work within.
- 03Detail beyond the top-line revenue growth is limited here; watch segment breakdowns and guidance for signals on supply and pricing.
From the source
Read at wsj.comEli Lilly Posts Higher Revenue on Continued GLP-1 Demand